423 related articles for article (PubMed ID: 11560200)
1. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
2. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study.
Slain D; Miller K; Khakoo R; Fisher M; Wierman T; Jozefczyk K
Clin Ther; 2002 Oct; 24(10):1636-42. PubMed ID: 12462292
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
4. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
5. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
6. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
7. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
9. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
Yang H; Chaudhari P; Zhou ZY; Wu EQ; Patel C; Horn DL
Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.
Sidhu R; Lash DB; Heidari A; Natarajan P; Johnson RH
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686150
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.
Prentice HG; Hann IM; Herbrecht R; Aoun M; Kvaloy S; Catovsky D; Pinkerton CR; Schey SA; Jacobs F; Oakhill A; Stevens RF; Darbyshire PJ; Gibson BE
Br J Haematol; 1997 Sep; 98(3):711-8. PubMed ID: 9332329
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
Wingard JR; White MH; Anaissie E; Raffalli J; Goodman J; Arrieta A;
Clin Infect Dis; 2000 Nov; 31(5):1155-63. PubMed ID: 11073745
[TBL] [Abstract][Full Text] [Related]
17. Renal effects of amphotericin B lipid complex.
Luke RG; Boyle JA
Am J Kidney Dis; 1998 May; 31(5):780-5. PubMed ID: 9590187
[TBL] [Abstract][Full Text] [Related]
18. COMPARATIVE EFFECTIVENESS AND SAFETY BETWEEN AMPHOTERICIN B LIPID-FORMULATIONS: A SYSTEMATIC REVIEW.
Grazziotin LR; Moreira LB; Ferreira MAP
Int J Technol Assess Health Care; 2018 Jan; 34(3):343-351. PubMed ID: 29897025
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary extraction and accumulation of lipid formulations of amphotericin B.
Matot I; Pizov R
Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature.
Martino R
Curr Med Res Opin; 2004 Apr; 20(4):485-504. PubMed ID: 15119986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
